Press release
Non-Alcoholic Steatohepatitis Pipeline 2024 | Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madr
Discover the latest drugs and treatment options in the Nonalcoholic Steatohepatitis Pipeline. Dive into DelveInsight's comprehensive report today! @ Nonalcoholic Steatohepatitis Pipeline Outlook [https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Nonalcoholic Steatohepatitis Pipeline Report
* July 2024:- Boston Pharmaceuticals- A Phase 2a, Randomized, Blinded, Placebo-controlled Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With a Single Arm Open-label Extension. This is a randomized, blinded, placebo-controlled study of BOS-580 in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH), with a single arm open-label extension. It includes Parts A, B, C and D.
* DelveInsight's Nonalcoholic Steatohepatitis pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Nonalcoholic Steatohepatitis treatment.
* The leading Nonalcoholic Steatohepatitis Companies such as Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics, and others.
* Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), and others.
Stay ahead with the most recent pipeline outlook for Nonalcoholic Steatohepatitis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Nonalcoholic Steatohepatitis Treatment Drugs [https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Nonalcoholic Steatohepatitis Emerging Drugs Profile
* Lanifibranor: Inventiva Pharma
Lanifibranor, Inventiva's lead product candidate, is an orally-available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPAR and PPAR, and a partial activation of PPAR. While other PPAR agonists target only one or two PPAR isoforms for activation. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of NASH. Currently, the drug is in Phase III stage of its clinical trial for the treatment of NASH.
* MSDC-0602K: Cirius Therapeutics
MSDC-0602K, a second-generation oral insulin sensitizer, is designed to selectively modulate the mitochondrial pyruvate carrier (MPC) while minimizing direct PPAR-gamma activation. The MPC mediates at the cellular level the effects of over nutrition, a major cause of Nonalcoholic fatty liver disease NAFLD/NASH and Type 2 diabetes. In preclinical studies, modulation of the MPC has been shown to improve insulin sensitivity, lipid metabolism, and inflammation. Currently the drug is in Phase III stage of Clinical trial for the treatment of NASH.
* TERN-501: Terns Pharmaceuticals
TERN-501 is a THR- agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR- compared to other THR- agonists in development. Agonism of THR- increases fatty acid metabolism via mitochondrial oxidation and affects cholesterol synthesis and metabolism. As a result, THR- stimulation has the ability to reduce hepatic steatosis and improve serum lipid parameters including LDL cholesterol and triglycerides. In vivo NASH studies in a rodent model have demonstrated that low-doses of TERN-501 achieved complete resolution of steatosis and reductions in serum lipids, hepatic inflammation and fibrosis. TERN-501 has high liver distribution and is 23-fold more selective for THR- than for THR- activation in a cell free assay, thereby minimizing the risk of cardiotoxicity and other off-target effects associated with non-selective THR stimulation. Currently, the drug is in Phase II stage of its clinical trial for the treatment of NASH.
* HTD 1801: HighTide Biopharma
The company's lead drug candidate, HTD1801, is a first-in-class new molecular entity (ionic salt of two active moieties). It is a novel orally active ionic salt of berberine and ursodeoxycholic acid, substantially reduced liver fat while improving glycemic control and other cardiometabolic biomarkers in adults with nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2DM). Currently, it is in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH).
Explore groundbreaking therapies and clinical trials in the Nonalcoholic Steatohepatitis Pipeline. Access DelveInsight's detailed report now! @ New Nonalcoholic Steatohepatitis Drugs [https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Nonalcoholic Steatohepatitis Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Nonalcoholic Steatohepatitis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Nonalcoholic Steatohepatitis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Nonalcoholic Steatohepatitis Pipeline Report
* Coverage- Global
* Nonalcoholic Steatohepatitis Companies- Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, Cirius Therapeutics, and others.
* Nonalcoholic Steatohepatitis Therapies- AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), and others.
* Nonalcoholic Steatohepatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Nonalcoholic Steatohepatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Nonalcoholic Steatohepatitis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Nonalcoholic Steatohepatitis Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Nonalcoholic Steatohepatitis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Nonalcoholic Steatohepatitis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Lanifibranor: Inventiva Pharma
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* TERN-501: Terns Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* LY3849891: Eli Lilly and Company
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name : Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Nonalcoholic Steatohepatitis Key Companies
* Nonalcoholic Steatohepatitis Key Products
* Nonalcoholic Steatohepatitis- Unmet Needs
* Nonalcoholic Steatohepatitis- Market Drivers and Barriers
* Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion
* Nonalcoholic Steatohepatitis Analyst Views
* Nonalcoholic Steatohepatitis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nonalcoholic-steatohepatitis-pipeline-2024-guangdong-raynovent-biotech-dr-falk-pharma-gmbh-enyo-pharma-viking-therapeutics-eli-lilly-and-company-sagimet-biosciences-terns-sinew-pharma-madr]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Alcoholic Steatohepatitis Pipeline 2024 | Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madr here
News-ID: 3611331 • Views: …
More Releases from ABNewswire
How to Pick the Best Online Chemistry Tutoring Platform
Image: https://www.abnewswire.com/upload/2025/10/814f4b38d9855ce5fcc0509bfebaa240.jpg
Choosing the right chemistry tutoring platform can make the difference between academic success and continued struggles with complex reactions and molecular structures. With students increasingly turning to digital solutions for personalized learning support, the online chemistry tutoring market has exploded with options promising everything from AI-powered progress tracking to virtual lab experiences that transform how learners approach this challenging subject.
Essential Platform Features for Effective Online Chemistry Tutoring
Modern chemistry tutoring…
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
Diabetic Retinopathy Pipeline Drugs Report 2025: Emerging Therapies, Clinical De …
DelveInsight's, "Diabetic Retinopathy Pipeline Insights 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by…
Diabetic Macular Edema Pipeline Outlook Report 2025: Emerging Therapies, Clinica …
DelveInsight's, "Diabetic Macular Edema Pipeline Insight 2025" report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Macular Edema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our…
More Releases for Steatohepatitis
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non-Alcoholic Steatohepatitis Treatment Market Size, Share
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Non-Alcoholic Steatohepatitis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $2.67 billion In 2028…
Non-Alcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023
Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance.
NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
Nonalcoholic Steatohepatitis Treatment Market Analysis
As per the research conducted by GME, the Global Nonalcoholic Steatohepatitis Treatment Market will grow with a CAGR value of 39.1% by 2026. Over the forecast era, the production of NASH biomarkers is expected to be aided by increasing demand for non-invasive diagnostic tools and increased patient awareness. The low use of invasive procedures for disease diagnosis is due to the high cost of liver biopsy, its invasiveness, and patients'…
Emerging Opportunities in Nonalcoholic Steatohepatitis Therapeutics Market
Global Nonalcoholic Steatohepatitis (NASH) Market: Snapshot
Nonalcoholic Steatohepatitis (NASH), a syndrome found in non-alcoholic patients, causes damage to liver that is histologically akin to alcoholic hepatitis. NASH results from fat in the liver, along with inflammation. Symptoms in NASH usually do not show, but it can be severe and lead to cirrhosis, which is permanent damage to the liver.
Those suffering from obesity, dyslipidemia, and glucose intolerance are most likely…
